Eli Lilly and Adocia agree to develop ultra-rapid insulin
December 19, 2014 at 01:41 AM EST
PARIS, Dec 19 (Reuters) - U.S. drugmaker Eli Lilly and French biotech Adocia said on Friday they agreed a worldwide licensing partnership to develop ultra-rapid insulin to treat patients with Type 1 and Type 2 diabetes.
